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4Summary 
This thesis focuses on the association between inflammation and body composition and 
consists of one cross sectional study in healthy overweight and in lean subjects (paper I), and 
one prospective study in patients with pancreatic cancer (papers II and III). In paper I, the 
relationship between inflammatory markers and body composition measured with 
anthropometry and bioelectrical impedance analysis (BIA) was examined in healthy 
individuals. Increasing hip circumference (HC) was associated with increasing levels of leptin 
and C-reactive protein (CRP) in both groups. CRP increased with increasing body mass index 
(BMI), also in the lean group. HC may be a proxy for fat percent measured with BIA in lean 
and overweight individuals, and may be useful for identification of people at risk of 
developing overweight-related disorders. In paper II the level of inflammatory markers, body 
composition, energy intake and development of cachexia was examined. Pancreatic cancer 
patients had higher levels of inflammatory markers compared with a healthy reference 
population at inclusion, and the levels increased as death approached. Weight, fat- and muscle 
mass were reduced during follow-up. At inclusion, there were no differences in the levels of 
inflammatory markers between patients who were classified as cachectic and those who were 
not. These results indicate that the increased levels of inflammation may be caused by the 
tumor and the tumor-host reactions. The third paper compared two classifications of cancer 
cachexia; the 3-factor classification that includes CRP as a criterion, and the consensus 
classification that includes sarcopenia as a criterion. Patients were categorized as cachectic 
and non-cachectic according to both classifications. Consistency across definitions was 
examined, as well as their ability to predict survival. The two classifications of cancer 
cachexia showed good overall agreement in defining cachectic patients, and cachexia was 
associated with poorer survival according to both. Inflammation in the body may be caused by 
fat mass and tumors. Overweight increases the risk for chronic diseases and pancreatic cancer. 
In cancer patients, the tumor may cause systemic inflammation, and cytokines may trigger 
weight loss and might be a driving force behind cachexia. Among pancreatic cancer patients, 
those with neither weight loss, reduced energy intake, systemic inflammation nor sarcopenia 
have the longest survival. We suggest that clinical interventions should be directed towards 
optimizing these risk factors in these patients.  
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Norsk sammendrag 
Denne avhandlingen består av en tverrsnittsstudie av friske overvektige og slanke personer 
(artikkel I) og en prospektiv studie av pasienter med kreft i bukspyttkjertelen (artikkel II og 
III). I artikkel I ble forholdet mellom inflammasjonsmarkører og kroppssammensetning målt 
med antropometri og bioimpedans (BIA), undersøkt i friske individer. Større hofteomkrets var 
assosiert med høyere plasmanivåer av leptin og C-reaktivt protein (CRP) i begge gruppene. 
CRP økte med økende kroppsmasseindeks, også blant de slanke. Hofteomkrets kan brukes 
som et surrogatmål på fettprosent, målt med BIA, og kan være nyttig for å identifisere de med 
risiko for overvektsrelaterte sykdommer. I artikkel II ble nivået av inflammasjonsmarkører, 
kroppssammensetning, energiinntak og utvikling av kakeksi undersøkt. Kreftpasientene hadde 
høyere nivåer av inflammasjonsmarkører sammenliknet med friske. Nivået av 
inflammasjonsmarkørene hos kreftpasientene fortsatte å øke fram mot død, samtidig som 
pasientene fikk redusert vekt, fett- og muskelmasse. Ved inklusjon i studien var det ingen 
forskjell i inflammasjonsmarkører mellom pasienter som ble klassifisert som kakektiske 
versus de ikke-kakektiske. Funnene kan tyde på at det er tumoren og kroppens reaksjon på 
tumoren som er årsak til økte nivåer av inflammasjonsmarkører. I den tredje artikkelen ble 
to klassifikasjoner av cancer kakeksi sammenliknet; 3-faktor klassifikasjonen som inkluderer 
CRP som et kriterium, og konsensusklassifikasjonen som inkluderer sarkopeni som et 
kriterium. Vi undersøkte om det var samsvar mellom klassifikasjonene i kategoriseringen av 
kakektiske pasienter, og hvilken av klassifikasjonene som best predikerte overlevelse. De to 
klassifikasjonene samsvarte godt i kategorisering av kakektiske og ikke-kakektiske pasienter 
og kakeksi var assosiert med dårligere overlevelse ifølge begge klassifikasjonene. Både 
fettmasse og kreft er assosiert med inflammasjon. Overvekt øker risikoen for kroniske 
sykdommer, inkludert kreft i bukspyttkjertelen. Hos kreftpasientene kan svulsten føre til en 
økning av inflammasjonsmarkører, deriblant cytokiner som kan påvirke vekttap og som kan 
være årsak til kakeksi. Pasienter med kreft i bukspyttkjertelen som verken hadde vekttap, 
redusert matinntak, systemisk inflammasjon eller sarkopeni, hadde lenger overlevelse enn 
pasienter der disse risikofaktorene var til stede. Kliniske intervensjoner bør derfor rettes mot 
disse risikofaktorene i denne pasientgruppen.  
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1 Introduction 
Overweight individuals and pancreatic cancer patients with cancer cachexia differ in weight 
and body composition and represent states of over- and undernutrition respectively. However, 
low-grade chronic inflammation probably contributes to metabolic alterations in both groups. 
The present study was undertaken to increase the knowledge about body composition and 
inflammation in over- and undernutrition and thereby contribute to the understanding of the 
role of inflammation in cancer cachexia. 
1.1 Obesity and pancreatic cancer 
A person is defined as overweight if the body mass index (BMI) is 25-30 kg/m² or obese if the 
BMI is above 30 kg/m² [1].The prevalence of overweight and obesity is increasing worldwide 
[2]. Currently 66% of the US population is overweight or obese and similar figures are 
reported globally, corresponding to 45% in Norway [3]. The main burden of obesity lies in the 
connection with diseases like insulin resistance and type 2 diabetes mellitus (T2DM) [4]. 
Adipose tissue plays an important role in the development of these diseases. Increased 
amounts of adipose tissue may lead to macrophage infiltration into the adipose tissue and a 
subsequent secretion of pro-inflammatory cytokines and acute phase proteins, such as C-
reactive protein (CRP), into the circulation [4, 5]. Furthermore; low-grade inflammation is 
considered an underlying cause of insulin resistance, T2DM [6, 7] and of many types of 
cancers [8], including pancreatic cancer [9]. 
In Norway, the estimated incidence of pancreatic cancer was 7.7% and 6.6% for men and 
women respectively in 2013 [10]. In general, pancreatic cancer is rare in patients younger 
than 40 years, and the median age at diagnosis is 71 years [11]. Pancreatic cancer, in which 
85% are pancreatic ductal adenocarcinomas, is usually diagnosed at an end stage when the 
tumor has metastasized into other organs such as the lungs and liver [11, 12]. The mortality 
exceeds 90%, and is higher in men than in women [11]. Surgery offers the only chance of a 
potential cure and adjuvant chemotherapy has shown a small increase in survival rates [13]. 
However only 15-20% of patients are considered candidates for surgery, because localized 
tumors are often infiltrated into local vessels [11, 14]. Consequently, palliative care, including 
palliative chemotherapy is the only treatment option for the majority of these patients [15, 
14 
16]. At the time of diagnosis, more than 80% of pancreatic cancer patients suffer from 
nutritional problems [17].  
Although obesity is a risk factor for pancreatic cancer [9], these patients are prone to weight 
loss due to inadequate energy and protein intake which may lead to malnutrition [18]. 
Malnutrition can be defined as a condition where energy and protein deficiency leads to a 
reduction in fat mass and fat-free mass (FFM) [19-21]. Recently, it has been proposed that 
diagnosis of malnutrition should be based on either a low BMI (<18.5 kg/m2), or on the 
combination of weight loss together with either reduced BMI (age-specific) or a low muscle 
mass using sex-specific cut-offs [19]. In malnourished patients, adequate symptomatic 
treatment and specific nutritional support will contribute to weight gain and a better 
nutritional state [18]. 
In patients with pancreatic cancer, malnutrition may be generated by different 
pathophysiological conditions caused by the tumor, such as duodenal stenosis, malabsorption, 
pancreatic insufficiency, constipation, malaise, taste alterations, early satiety and loss of 
appetite [15, 22]. The condition may be worsened by side effects from anti-cancer treatment, 
i.e. chemotherapy, which may cause nausea, vomiting and changes in smell and taste, with
frequent aversion to specific foods or food in general [15]. Chemotherapy can also lead to
problems in the digestive system, affecting both the ability and desire to eat and also the
absorption of nutrients, thus contributing to increasing anorexia [15]. However, chemotherapy
may also prolong survival and improve quality of life (QoL), thus the administration of
chemotherapy must be balanced against side effects [23, 24].
1.2 Cancer cachexia 
The word cachexia stems from the Greek words kako`s and he`xis, meaning “bad condition” 
[25]. Cancer cachexia emerges from a complex interaction between cancer growth and host 
response resulting in progressive weight loss that is a consequence of a negative protein and 
energy balance, often associated with signs of inflammation [15].  
The syndrome is multifactorial and characterized by anorexia, fatigue and involuntary weight 
loss, i.e. ongoing loss of skeletal muscle mass, with or without the loss of fat mass [15, 22, 
26]. It is also associated with poor tolerability of cancer treatment, decline in performance 
status and reduced QoL and survival [27-29]. As opposed to malnutrition, weight loss in 
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cachexia cannot be compensated by optimal energy intake [27, 28]. In addition, metabolic 
alterations in cachexia cause greater loss of muscle mass than in malnutrition, where lean 
body mass is preserved [15, 18]. 
Loss of skeletal muscle mass and adipose tissue may lead to low albumin levels and fatigue, 
which limits physical activity and accordingly inhibits protein synthesis [15]. Muscle wasting 
may be accelerated by a combination of metabolic changes (i.e. increased resting energy 
expenditure and increased turnover of protein, lipids and glucose), hormonal changes (i.e. 
insulin resistance), systemic inflammation (i.e. cytokine release) and tumor-inducing factors 
(i.e. proteolysis-inducing factor (PIF)) [15, 22]. Moreover, the loss of adipose tissue is caused 
by a combination of the tumor-inducing factor, lipid mobilizing factor (LMF) [22], and 
cytokines [30] that contribute to a disturbance of lipid metabolism causing increased lipolysis, 
which is considered a key factor in triggering the loss of adipose tissue [31, 32].  
Although several factors involved in the development of cachexia are described, the 
underlying mechanisms remain unclear [26, 33]. Because of this and because of the fact that 
cachexia is associated with a wide range of clinical manifestations it is difficult to precisely 
define this condition. This makes it difficult to estimate the prevalence of cancer cachexia 
[34]. The prevalence rates in cancer patients vary between 12% and 82% depending on 
definitions, study designs and patient samples [35-37]. However, even with the same tumor 
type and stage of disease, one patient may develop cachexia whereas another may not. Such 
variation may relate, at least in part, to the host genotype [38, 39]. It is estimated that cancer 
cachexia accounts for about 20% to 40% of all cancer deaths [40, 41]. In order to identify, 
treat and/or prevent this condition and to develop potential therapeutic interventions, there is 
an urgent need of a consensus definition that is accepted by clinicians and researchers [26].  
1.2.1 Definitions of cancer cachexia 
Due to the lack of an established definition of cancer cachexia, involuntary weight loss of 
10% or more has been used as a diagnostic criterion for cancer cachexia [42]. However, 
weight loss alone is often not enough to capture the complexity of cachexia, as a substantial 
loss of muscle mass may be concealed by edema and/or overweight [43]. Furthermore, weight 
loss is not sufficient to explain deterioration in physical function, which is a characteristic 
feature of cancer cachexia [37, 44].  
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A universally accepted definition of cancer cachexia has therefore been requested. In order to 
follow a consensus process to define cachexia, three expert groups were established in 2006 
(Table 1); (i) An expert meeting organized by the Society of Cachexia and Wasting disorders 
(SCWD) [26], (ii) The Special Interest Group (SIG) on Cachexia-Anorexia in chronic wasting 
disease created within The European Society for Clinical Nutrition and Metabolism (ESPEN) 
[45], and (iii) The European Palliative Care Research Collaborative (EPCRC) [25]. 
Table 1: Consensus definitions of cancer cachexia
The common focus of the definitions from SCWD, ESPEN and EPCRC was loss of skeletal 
muscle mass (with or without loss of fat mass) and the subsequent loss of functional capacity.  
Year of 
publication
Special interest groups and 
definitions
2008
Evans et al. 
[26]
Society of Cachexia and Wasting disorders 
Cachexia is a complex metabolic syndrome associated with underlying illness and characterized by 
loss of muscle with or without the loss of fat mass. The prominent clinical features of cachexia is 
weight loss in adults and growth failure in children. Anorexia, inflammation, insulin resistance and 
increased muscle protein break down are frequently associated with wasting disease. Wasting 
disease is distinct from starvation, age-related loss of muscle mass, primary depression, 
malabsorption and hyperthyroidism and is associated with increased morbidity.  
2010
Muscaritoli et al. 
[45]
The Special Interest Group on Cachexia-Anorexia in chronic wasting disease created within The 
European Society for Clinical Nutrition and Metabolism 
Cancer cachexia is a multifactorial syndrome characterized by severe body weight loss, muscle and 
fat loss and increased protein catabolism due to underlying disease(s). Cachexia is clinically relevant 
since it increases patient’s morbidity and mortality. Contributory factors to the onset of cachexia are 
anorexia and metabolic alterations, i.e. increased inflammatory status, increased muscle proteolysis, 
and impaired carbohydrate, protein and lipid metabolism. Considering the wide range of clinical 
manifestations of cachexia, the staging of this syndrome is warranted. 
2010
Argiles et al. 
[25]
The European Palliative Care Research Collaborative 
Cancer cachexia is a multifactorial syndrome defined by a negative protein and energy balance 
driven by a variable combination of reduced food intake and abnormal metabolism. A key defining 
feature is ongoing loss of skeletal muscle mass, which cannot be fully reversed by conventional 
nutritional support, leading to progressive functional impairment.
2011
Fearon et al. 
[44]
Representatives of the above mentioned expert groups
Cancer cachexia is a multifactorial syndrome characterized by an ongoing loss of skeletal muscle 
mass (with or without the loss of fat mass) that cannot be fully reversed by conventional 
nutritional support and leads to progressive functional impairment. The pathophysiology is 
characterized by negative protein and energy balance driven by a variable combination of reduced 
food intake and abnormal metabolism. 
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With the intention to reach a more specific definition of cancer cachexia and a classification 
based on a formal consensus process, representatives from the three groups participated in a 
Delphi process in 2009. An international consensus definition was reached in 2011 [44] 
(Table 1): “Cancer cachexia is a multifactorial syndrome characterized by an ongoing loss of 
skeletal muscle mass (with or without the loss of fat mass) that cannot be fully reversed by 
conventional nutritional support and leads to progressive functional impairment. The 
pathophysiology is characterized by negative protein and energy balance driven by a variable 
combination of reduced food intake and abnormal metabolism”. A set of criteria for a 
classification was defined of which one of the following had to be present: weight loss more 
than 5% over the past 6 months (in absence of simple starvation), BMI <20 kg/m2 and any 
degree of weight loss >2%, or appendicular skeletal muscle index consistent with sarcopenia 
and any degree of weight loss >2% (Table 2). 
Previously, several diagnostic criteria were proposed (Table 2). Between 2002 and 2004, the 
North Central Cancer Treatment Group (NCCTG) [46-48] classified cachexia as involuntary 
weight loss, anorexia or impaired oral nutritional intake, in phase III studies. In 2006, Fearon 
et al [37] incorporated systemic inflammation in a three-factor classification of cancer 
cachexia based on a study of weight-losing pancreatic cancer patients. The presence of two 
out of the three factors i.e. weight loss, reduced food intake and systemic inflammation, was 
shown to have impact on objective (i.e. hand-grip strength and Karnofsky performance score) 
and subjective (i.e. physical function, dyspnea and fatigue) function [37]. Furthermore, in 
2009, the Screening Nutritional Risk in Oncology (SCRINIO) working group suggested a 
classification that could be feasible for clinical practice, until more specific diagnostic 
measures were available. They proposed four stages of severity of cancer cachexia based on 
weight loss of less than 10% (pre-cachexia) or more than 10% (cachexia) and on the absence 
or presence of three symptoms i.e. anorexia, early satiety or fatigue. The classifications are 
either asymptomatic pre-cachectic (class 1), symptomatic pre-cachectic (class 2), 
asymptomatic cachexia (class 3) or symptomatic cachexia (class 4) [33]. The criteria for 
classification in the consensus definition include elements from all of the previous criteria, but 
food intake, identification of inflammation and symptom mapping are not included.  
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Table 2: Overview of proposed diagnostic criteria of cancer cachexia 
¹MUAMC = mid-upper-arm muscle circumference <10th percentile for age and gender, ²DEXA = Dual X-ray 
absorptiometry: men <7.25 kg/m²; women <5.45 kg/m², ³ increased inflammatory markers: CRP: >5.0 mg/l,    
IL-6 >4.0 pg/ml, anemia: <12g/dl, low serum albumin <3.2 g/dl, ͣ Symptoms were classified according to a 4-
point score; 1=no symptoms, 2= mild symptoms, 3= moderate symptoms, 4= severe symptoms, ᵇCT imaging: 
men <55 cm²/m², women <39 cm²/m². 
It was emphasized that cachexia can develop progressively through various stages (Figure 1). 
The spectrum starts with pre-cachexia, then develops to cachexia and finally to refractory 
cachexia. The progression can be modulated by factors like cancer type and stage, systemic 
Year of publication and 
author 
Studies and Classifications 
2002-2004 
Jatoi et al. [46-48] 
The North Central Cancer Treatment Group studies. 
x weight loss: 2% in 2 months or 5% in 6 months 
x anorexia: visual analogue scale >3/10, (0 no problem and 10 maximal problem) 
x reduced food intake: <75% than normal or  <20 kcal/kg body weight/day 
2006 
Fearon et al. [37]  
Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic 
inflammation on functional status and prognosis. 
Minimum 2 of the 3 factors should be met:  
x Weight loss >10% 
x Low food intake (<1500 kcal)  
x CRP >10 mg/l 
2008 
Evans et al. [26] Cachexia: a new definition. 
Classified by: weight loss of at least 5% in 12 months or less (or BMI <20 kg/m²), plus three of 
the following criteria:  
x decreased muscle strength (lowest tertile) 
x fatigue (physical and/or mental weariness resulting from exertion) 
x anorexia (limited food intake: <75% than normal or <20 kcal/kg body weight/day) 
x low fat free mass index (lean tissue depletion measured by MUAMC¹ or DEXA²) 
x abnormal biochemistry³ (increased inflammatory markers, anemia, low serum albumin)  
2009 
Bozzetti et al. [33]  
Defining and classifying cancer cachexia: a proposal by the SCRINIO working group. 
weight loss (<10%, pre-cachexia; >10%, cachexia) and at least one cachexia-related symptom ͣ : 
x anorexia 
x fatigue 
x early satiety  
2011 
Fearon et al. [44] 
Definition and classification of cancer cachexia: an international consensus. 
One out of 3 criteria should be met:  
x weight loss <5% over past 6 months (in absence of simple starvation); or 
x BMI <20 kg/m², and any degree of weight loss >2% or 
x appendicular skeletal muscle index consistent with sarcopeniaᵇ  and any degree of weight 
loss >2% 
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inflammation, reduced food intake and response to anticancer therapy. Not all patients 
experience all stages [49]. Cancer cachexia has traditionally been associated with advanced 
disease [34]; however, it is now recognized as an early occurrence in the development of 
cancer [50]. 
Figure 1: Stages of cancer cachexia 
Modified from Fearon et al. [44] 
The international consensus definition is considered a framework that can be modified over 
time [44]. Thus, efforts to validate this definition in clinical studies are important [25, 44]. 
Wallengren et al. [35] compared the consensus definition [44], and the classifications by 
Fearon et al. [37] and Evans et al. [26] in 405 patients with different cancer diagnoses in 
advanced stages. The conclusion was that weight loss, fatigue and markers of systemic 
inflammation were most strongly associated with adverse outcomes like reduced QoL, 
functional decline, more symptoms and shorter survival. Based on the results, an alternative 
three-factor classification was developed; weight loss >2% since before onset of disease, 
fatigue >3 points (on a 1-10 scale), and CRP >10 mg/l. Blum et al [51] also validated the 
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consensus definition in a heterogeneous sample of patients with advanced cancer. They 
concluded that the combination of weight loss and low BMI showed the strongest association 
with short survival. 
Considering the limited treatment options for cancer cachexia, emphasis is put on pre-
cachexia, in which multi-modal interventions may slow down weight loss [49]. However, 
discrepancy in the prevalence of pre-cachexia was found in two recent studies in patients with 
advanced cancer and no significant difference in survival was found between pre-cachexia 
and cachexia [51, 52]. Moreover the clinical relevance of pre-cachexia has been questioned, 
as an unpublished study by Blauwhoff-Buskermolen et al. showed that the use of the present 
framework depicted in Figure 1 identified very few patients i.e. 0.5-2% [53].  
1.3 Inflammation  
Inflammation is the body’s defense against infections or damaged tissue following i.e. 
surgical trauma or tumor surgery [54, 55], and is the body’s attempt to remove the harmful 
stimuli and to initiate the healing process (6).  
The localized inflammatory responses co-occur with a large number of systemic and 
metabolic changes referred to as the acute phase response [54]. Primarily the response 
involves the innate immune system through secretion of cytokines and interleukins by 
activated macrophages. Clinically, the acute phase response is characterized by inflammation, 
anorexia, increased vascular permeability, vasodilatation and increased cardiac output, as well 
as neuro-endocrine and metabolic changes [54]. CRP is a well described acute phase protein 
and is known for its clinical application as a marker for systemic inflammation [56, 57]. CRP 
levels reported in healthy individuals is usually less than 3 mg/l, [58, 59], but can rise 1000-
fold in severely infected individuals [54]. Therefore, the CRP levels can indicate the severity 
of an inflammatory response [60] and CRP >10 mg/l is used as an indication of the acute 
phase response [61].   
Acute inflammation has a relatively short duration, lasting from minutes to a few days [62]. 
Important proteins involved in the inflammatory response are the cytokines, which is a large 
group of small proteins [63, 64] and include the pro-inflammatory molecules interleukin (IL) -
1 , IL-6, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and the anti-inflammatory 
cytokine IL-10 [65]. These proteins may activate and influence each other [66]. TNF-α as 
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well as IL-1β and IL-6, activate the NF-κB transduction pathway and thus stimulate further 
cytokine production [67, 68]. IL-10, on the other hand, inhibits the actions of e.g. IL-6, as the 
special physiological role of IL-10 is to prevent and limit tissue damage by limiting 
overwhelming immune reactions [69].  
The inflammatory response in obesity differs in duration and intensity from an inflammatory 
response caused by pathogens/infections. When infectious inflammation involves short-lived, 
high amplitude responses [62], adipose tissue inflammation occurs at low levels for years to 
decades, and therefore the term chronic low-grade inflammation is used to describe the 
inflammation caused by obesity [4, 6, 7]. Obesity causes a recruitment and infiltration of 
macrophages to the adipose tissue, and is the initial event in obesity-induced inflammation 
[70, 71]. They secrete a variety of cytokines, such as TNFDIL-1β and IL-6, which can act 
locally in a paracrine manner, or they leak out of the adipose tissue [65], causing a systemic 
effect (endocrine action) on insulin sensitivity in insulin target cells, which again may lead to 
insulin resistance [6, 7]. Furthermore, obesity is also linked to adipocyte hypertrophy and 
hypoxia, aggravating the inflammatory state [70, 72]. Moreover, sustained inflammatory 
signaling, insulin resistance and hypoxia cause a microenvironment favorable for tumor 
development [72, 73].  
Obesity-induced activation of intracellular pathways, such as NF-κB are major mediators in 
pancreatic cancer, causing elevated concentrations of TNFα, IL-1β, IL-6, IL-10 and growth 
factors [74]. In the presence of a tumor, cytokines are also secreted by skeletal muscle (e.g. 
the myokine TGFβ) lymphocytes and the tumor itself [30, 34, 74] thus cytokine levels 
increase with tumor progression [75]. Increased levels of cytokines act locally in 
hypothalamus and are thought to be responsible for anorexia, elevated resting energy 
expenditure and weight loss [76]. They may also cause other symptoms like fatigue, anemia 
and protein degradation [39]. Whether these symptoms occur as independent processes or are 
direct results of the inflammatory process of cancer cachexia is not fully understood [15]. 
TNF-α is also called cachectin [39] and is known to play a critical role in cancer cachexia [65, 
77]. IL-6 is recognized as the main mediator of the hepatic acute phase response in humans 
and a driving force of systemic inflammation in cancer cachexia [39]. Moreover, it is known 
to inhibit synthesis and enhance catabolism of lipids and proteins in adipocytes and myocytes 
respectively [65].  
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1.4 Body composition and disease 
Body composition refers to the distribution and amount of FFM and fat mass (i.e. adipose 
tissue) in the human body [43]. The FFM is everything that is not fat mass (Figure 2) [78] and 
consists of extracellular and intracellular water, bone mineral and total body protein, 
including visceral protein and skeletal muscle mass. Intracellular water and total body protein 
are components of the body cell mass (BCM). The BCM is the protein-rich compartment that 
is affected during catabolism. Loss of BCM (i.e. skeletal muscle mass) [78, 79], which occurs 
with ageing and diseases like cancer, chronic heart disease and pulmonary disease, has 
important implications for QoL, physical function and survival [76, 80].  
Figure 2: Body composition compartments  
Schematic diagram of FFM, total body water, intracellular water, extracellular water and 
BCM. Modified from Kyle et al. [78].  
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1.4.1 Skeletal muscle mass and adipose tissue 
Skeletal muscle activity influences metabolism by producing and consuming energy [81]. 
Skeletal muscle mass is controlled by the balance between protein synthesis and proteolysis. 
Protein synthesis is mainly regulated by insulin, insulin-like growth factor-1 (IGF-1) and 
activity, while proteolysis is regulated by inflammation and inactivity [82]. Skeletal muscle 
also act as an endocrine organ by producing and releasing inflammatory markers, termed 
myokines, which exerts local effects on signaling pathways involved in muscle metabolism 
and endocrine effects on other organs [65, 83]. Myokine IL-6 is normally released by 
contracting skeletal muscle cells, and is important for muscle metabolism during exercise 
[83]. It mediates the anti-inflammatory properties of exercise by modulating TNF-α levels and 
stimulating IL-10 production. Myokine IL-6 does not activate the NF-κB signaling pathway 
but other pathways promoting insulin sensitivity [83]. In contrast to this, elevated levels of 
serum IL-6 synthesized by adipocytes and immune cells are associated with insulin resistance 
[84]. 
The adipose tissue is an important metabolic organ, consisting of white adipose tissue (WAT), 
dominated by white adipocytes and brown adipose tissue (BAT), dominated by brown 
adipocytes [85]. There are two representative types of WAT: Visceral adipose tissue, which is 
mostly localized in the abdominal cavity [86], and subcutaneous adipose tissue, which lies 
immediately under the skin and in the intramuscular fat. Subcutaneous adipose tissue is 
largely found in the lower trunk (e.g. hips) [85]. The abdominal cavity is drained by the portal 
vein [7], and thus visceral obesity may cause a release of non-esterified fatty acids directly 
into the portal vein and to the liver, causing metabolic alterations and insulin resistance [84]. 
In addition to adipocytes, the WAT also consists of inflammatory cells. In lean subjects, these 
inflammatory cells are involved in maintaining a normal response to insulin [71, 87]. As 
obesity develops, these adipocytes start to secrete chemokines that attract monocytes into the 
adipose tissue to develop into macrophages that cause low grade chronic inflammation as 
described above [88]. The main function of white adipocytes is to store energy (as 
triacylglycerol) in large cytoplasmic lipid droplets. Most adipose tissue in humans is WAT, 
and this is also the main site of energy storage in the body [85, 88]. Brown adipocytes also 
store triacylglycerol, but in contrast to white adipocytes they have a high number of 
mitochondria and many small cytoplasmic droplets [85]. The main function is to regulate 
thermogenesis by transferring energy from food into heat with its characteristic protein, 
24
uncoupling protein (UCP)-1 [85]. In animal models of cancer cachexia, chronic inflammation 
(i.e. cytokines and myokines) has shown to cause an increase of UPC-1 expression and a 
following switch from WAT to BAT, called WAT browning [65, 83, 89]. WAT browning 
takes place in the initial stages of cachexia, before skeletal muscle atrophy and may be 
responsible for an increase in energy expenditure and loss of adipose tissue [89, 90]. 
1.4.2 Adipose tissue as an endocrine organ 
The white adipocytes secrete hormones, termed adipokines that regulate food intake (i.e. 
leptin) and modulate immunity and inflammation [91]. They also effect various metabolic 
pathways such as growth hormone signaling, insulin sensitivity and lipogenesis [76].  
The hormones may act locally and/or at a systemic level and provide an important link 
between obesity, insulin resistance, and related disorders [86], as they modulate energy 
metabolism, influence insulin sensitivity [92], and affect the innate immune system by either 
suppressing or activating cytokine production [86]. 
Leptin is a product of the obese gene secreted by adipocytes in proportion to fat mass. It has 
been recognized to play a major role in long-term regulation of body mass by affecting the 
balance between two pathways that control energy expenditure and food intake within the 
hypothalamus; the orexigenic pathway that stimulates energy intake, and the anorexigenic 
pathway that inhibits energy intake [18, 22]. Leptin crosses the blood-brain barrier in a 
process that is highly regulated; low leptin levels are compensated by an increase in appetite 
and a decrease in energy expenditure, and high leptin levels are followed by reduced appetite 
and stimulation of fat oxidation and increased energy expenditure [76]. 
Leptin has been shown to upregulate the production of inflammatory cytokines [86]. Leptin 
binding proteins e.g. CRP can bind leptin in blood, and limit leptin receptor binding and 
transport across the blood-brain-barrier [76]. In cases of increased body fat, this may cause a 
desensitizing of leptin, a condition known as leptin resistance [76].  
Resistin is another adipokine known to be positively correlated with BMI, but although BMI 
is a significant predictor of insulin resistance, resistin is not [93]. Many aspects of the role of 
resistin on insulin resistance in humans are unclear, however it is recognized to inhibit insulin 
action and increase insulin resistance [86]. Moreover, resistin may play a role in cell 
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proliferation and differentiation, and chronic inflammatory reactions associated with 
overweight/obesity [86], by up regulating cytokine production via the NF-κB pathway [65].  
Adiponectin on the other hand is inversely associated with overweight and abdominal 
obesity. This hormone is inversely associated with fat mass and hence high levels are found in 
lean individuals [93]. Adiponectin may protect against insulin resistance and atherosclerosis 
by decreasing blood glucose concentrations, and by limiting circulating fatty acids and 
triglycerides in muscles and liver [93].  
1.5 Motivation for this thesis 
It is generally agreed that cytokines induce and are the driving forces behind cancer cachexia, 
and that muscle mass is reduced during the cancer cachexia trajectory. The syndrome is 
thought to be present in the majority of patients with pancreatic cancer, but little is known 
about how cytokines and the specific secretion of adipokines from adipose tissue are 
associated with body composition and how this changes during the disease trajectory. 
Tumors, as well as dysfunctional adipose tissue and muscle tissue, probably cause an 
environment that enhances the production of cytokines, adipokines and myokines. However, 
for most of the inflammatory markers, there are no established reference values, but obesity 
evidently leads to a chronic low-grade inflammation and causes an increase in pro-
inflammatory cytokines followed by alterations in energy metabolism.  
The consensus definitions of cachexia recognize muscle loss as a hallmark and include this as 
one of the classification criteria. However, the suggested set of criteria is not well validated in 
clinical studies and their consistency in defining cachectic and non-cachectic cancer patients 
is rarely investigated. The fact that we lack a universally accepted and validated cachexia 
definition may have therapeutic consequences, as the condition is not recognized at an early 
stage, and because optimal interventions to treat or postpone cachexia are not implemented. 
The main motivation for this study was to study the relationship between inflammatory 
markers and body composition in healthy individuals within different BMI categories. We 
also wanted to study cancer cachexia and the role of inflammation in a cohort of patients with 
pancreatic cancer. Finally, we wanted to study the consistency of two definitions of cancer 
cachexia in the same patient group and their ability to predict survival.  
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2 Aim 
The overall aim of this thesis was to gain more knowledge about cancer cachexia and to 
investigate the relationship between body composition and inflammation in two different 
samples; healthy individuals and patients with pancreatic cancer. To address this aim we 
specifically asked: 
I What is the relationship between fat- and lean body mass and inflammatory markers 
and adipokines in healthy individuals, both overweight and lean? (paper I)  
II How do inflammation and fat- and muscle mass develop from the time of diagnosis 
towards death in pancreatic cancer patients? How is the inflammatory profile in non-
cachectic and cachectic patients, defined according to the 2011 consensus definition? 
(paper II)  
III Is there a consistency between two established definitions of cancer cachexia in the 
classification of cachectic patients and in their ability to predict survival? (paper III) 
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3 Materials and methods 
This thesis consists of two separate studies, one in healthy individuals and one in patients with 
pancreatic cancer (Table 3).  
Table 3: Designs of the studies 
 Study I Study II 
Design Cross-sectional study  Prospective study 
 
Paper I  II III 
Participants 47 healthy overweight 
(BMI 26-49 kg/m² ) and 40 
healthy lean individuals 
(BMI<25 kg/m²)    
 
20 pancreatic cancer 
patients  
45 pancreatic cancer patients  
Methods Anthropometry 
Bioelectrical impedance 
Venous blood samples  
Anthropometry 
Bioelectrical 
impedance 
Venous blood samples   
Hand grip strength  
24 hour recall 
Computed tomography 
imaging 
CRP from routine blood 
testing  
Height from medical records 
Self- reported weight from 
questionnaires from a 
hospital database 
Location Oslo and Akershus 
University College of 
Applied Sciences 
Oslo University 
Hospital, Ullevål 
Oslo University Hospital, 
Ullevål  
 
3.1 Participants 
The reference data collected in study I was collected at a single time point in a cross-sectional 
study conducted at Oslo and Akershus University College of Applied Sciences. The 
overweight individuals were subjects available for baseline analysis in a contemporary 
intervention trial performed in 2009 [94]. They were approached through mass media and 
selected in accordance with certain inclusion criteria. In 2010, a reference group of lean 
subjects was recruited in the same way as the overweight individuals. The study aimed to 
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investigate associations between inflammation markers, adipokines and fat mass in a healthy 
overweight or lean population (study I).  
In October 2008, Oslo University Hospital (OUH) established a multidisciplinary research 
program on pancreatic tumors including all patients who were admitted to the Department of 
surgery, gastric medicine or oncology with suspected or documented solid or cystic pancreatic 
or periampullary neoplasms (study II). Standard evaluation included medical history, physical 
examination, routine laboratory tests, tumor markers, and contrast-enhanced helical CT of the 
abdomen and thorax in three vascular phases [95, 96]. The aim was to increase the knowledge 
about pancreatic tumors and the consequences on patient reported outcomes and to improve 
the treatment and follow-up of the patients. After written consent, clinical data, diagnostic and 
treatment related-issues, results from blood tests, tumor tissue and cyst fluid and patients’ 
self-reported symptoms were collected prospectively once a month until death.  
Data from study II formed the basis for papers II and III. Paper II stems from a prospective 
study of inoperable pancreatic cancer patients who were referred to the Palliative Care Unit at 
OUH-Ullevål between March 2010 and January 2012. Patients were first included in the 
pancreatic project, then asked to participate in study II. Body composition, inflammatory 
markers and food intake were registered once a month from the time of diagnosis until death, 
and associations with inflammatory markers were examined. Paper III is based on a 
prospective study of pancreatic cancer patients, referred between January 2008 and December 
2011. Some of the patients from study II were included in paper III. In addition, data were 
retrieved from patient records and the database of the pancreatic project. The aim was to 
explore consistencies between two definitions of cancer cachexia and their association with 
survival.  
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3.2 Methods 
3.2.1 Measurements of body composition 
Anthropometry 
Changes in body composition may show the integrated effect of a period of metabolic 
imbalance [79]. Anthropometric measurements are measurements of the size, weight and 
proportions of the human body, and are useful tools for localization and determination of the 
amount of fat and muscle mass. Anthropometry can be used as a  quick assessment of 
nutritional status and to identify undernutrition, overweight and obesity [97]. 
Classical anthropometric measurements include weight, height, waist circumference, hip 
circumference, triceps skin fold (TSF) thickness, mid-upper-arm circumference (MUAC) and 
hand grip strength. Weight is measured by a weight scale and height is measured by a wall-
mounted stadiometer. BMI is calculated as weight (kg)/height squared (m²). Waist and hip 
circumferences are measured with a standard non-stretch tape. Waist circumference and the 
waist-hip circumference ratio (waist circumference divided by hip circumference) (WHR) are 
useful indicators of abdominal obesity (i.e. visceral and subcutaneous fat), and hip 
circumference may reflect the amount of subcutaneous fat in the lower trunk (i.e. hip and 
buttocks) [98, 99]. Waist circumference has been more strongly associated with total body fat 
measured with DEXA than WHR, and it has been more closely related to metabolic 
disturbances associated with abdominal obesity [100].  
Skin fold thickness at the triceps muscle i.e. TSF, is measured by a Harpenden caliper and 
indicates the amount of subcutaneous fat. The mid-upper-arm circumference (MUAC) can be 
measured with a standard non-stretch tape. The MUAMC can be calculated from these 
measurements with the equation: MUAC – (π x (TSF/10)) = MUAMC (cm²). The 
combination of the measurements provides a simple estimate of subcutaneous fat mass and 
muscle mass, respectively [100]. Hand grip strength assesses upper extremity muscle strength 
and is measured using a dynamometer, which can test hand grip strength up to 90 kg. In 
community studies of older adults poor hand grip strength has been related to poor nutritional 
status defined as low BMI [100].  
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Body composition analysis: bioelectrical impedance analysis and Computer 
Tomography 
Impedance and imaging can be used to provide accurate estimates of body composition, as the 
methods permits separation of skeletal muscle and adipose tissue. 
The use of bioelectrical impedance analysis (BIA) is widespread both in healthy subjects and 
patients [78] and is widely used in clinical research for analyses of nutritional status (16). BIA 
allows the determination of the FFM and TBW in subjects without significant fluid and 
electrolyte abnormalities [78]. BIA is practical, safe, cost-effective, portable, quick and 
convenient for the patient, and easy to use [43, 101]. The method relies on population-specific 
regression equations, is shown as a good tool in large-scale epidemiologic studies [102]. In 
papers I and II, weight and body composition were measured with a Tanita scale (BC-418 
MA, Tanita Corp., Tokyo, Japan), operating at 50 kHz.  
BIA involves attaching electrodes to the hands and feet of a person and sending a small, and 
clinically negligible, electrical signal through the body [98, 100]. The method measures 
resistance from the electrical signal based on the fact that FFM has a higher water- and 
electrolyte content than fatty tissue and therefore has a higher electrical conductivity and 
lower impedance [43, 100]. BIA measures TBW, which is then used to estimate FFM and fat 
mass. Standardized procedures must be used to obtain BIA measurements. Hydration status, 
recent physical activity and consumption of food or beverages, are among the factors that can 
affect the validity and the precision of the measurements [78, 100]. However, BIA has shown 
limited applicability in those with BMI >34 kg/m² as it may overestimate FFM and 
underestimate fat mass [43].  
Computer Tomography (CT) is based on the relationship between the degree of attenuation of 
an X-ray beam and the density of the tissue through which the beam has passed. From this 
relationship, a two dimensional radiographic image of the underlying anatomy of the scan 
area can be constructed [103]. CT scans used for analysis in paper III were performed for 
initial cancer staging and routine diagnostic purposes. Patients who had an abdominal CT 
scan taken within 30 days before or 10 days after diagnosis were selected for the study. One 
CT image, at the level of the third lumbar vertebra (L3) was assessed, and was the image in 
which both transverse processes were first clearly visible [104]. The muscles in the area of the 
L3 encompass psoas, erector spinae and quadratus lumborum, as well as transversus 
abdominus, external and internal oblique abdominals, and rectus abdominus [104]. The scans 
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were analyzed with the software program Slice-O-Matic V4.3 (Tomovision, Montreal, 
Canada) which enables specific tissue demarcation using Hounsfield unit (HU) thresholds that 
are based on a linear scale using water as reference (0 HU). Skeletal muscle was quantified by 
HU thresholds of -29 to +150 [105]. The L3 region is chosen as a landmark for CT images 
because the skeletal muscle area 5 cm above the L4-L5 has been shown to correlate strongly 
with total body skeletal muscle volume in a healthy population [32]. Muscle area was 
normalized for height in meters squared (m²), and reported as muscle index (cm²/m²). The 
same was done for fat mass, which was reported as fat mass index. Indices of FFM and fat 
mass (kg/m²) were calculated by using regression equations developed by Mourtzakis et al 
[106]. All CT images were identified and analyzed by the same single trained observer. Cut-
offs in the consensus definition of cancer cachexia are gender specific and set at 55 cm²/m² 
for men and 39 cm²/m² for women [44].  
3.2.2 Preparation of blood samples 
Blood samples from healthy lean and overweight participants were prepared using identical 
procedures (paper I). Venous blood samples were collected after an overnight fast (> 12 
hours) between 8 am and 10 am by authorized health personnel. Serum from the overweight 
and lean was obtained from silica gel tubes, kept on ice and centrifuged (1500 g for 12 min), 
aliquoted and stored at -80 ºC until further analyses, or kept in room temperature for at least 
30 min, until centrifugation and immediately prepared for subsequent analyses. Plasma was 
obtained in EDTA tubes, kept on ice, centrifuged (2000 g, 4ºC for 10 min), within 15 min. 
The same procedures were applied for blood samples from the pancreatic cancer patients 
(paper II), except that patients were not asked to fast, serum was stored at room temperature 
for at least 45 min until centrifugation, and plasma samples were centrifuged (2500 g, for 15 
min), within 10 min. All blood samples from these patients were stored at -80 until further 
analysis.  
Serum levels of the adipokines resistin (paper I), leptin and adiponectin (papers I and II) and 
the cytokines IL-10, INFJ and TNF-D (paper II), and plasma levels of IL-6 and IGF-1 (paper I 
and II) were measured by enzyme immunoassays from R&D Systems (Minneapolis, USA) 
according the manufacturer’s instructions. All analyses were performed in duplicates. The 
coefficients of variation for intra-assay and inter-assay variability were <5% and <10%, 
respectively, for all analyses. Standard blood chemistry (including CRP) and lipid parameters 
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of healthy individuals were measured in serum or in EDTA plasma at Fürst Medical 
Laboratory (Oslo, Norway) using routine methods (paper I). Results from standard blood 
chemistry and CRP of pancreatic patients were retrieved from the medical records (papers II 
and III). 
3.2.3  Evaluation of food intake 
Subjective global assessment 
The Subjective Global Assessment (SGA) [107, 108] is a validated questionnaire that 
measures nutritional status based on the features of medical history; e.g. weight changes and 
dietary intake, and physical examination; e.g. loss of subcutaneous fat and muscle wasting 
(Appendix 1). The SGA has been found to be highly predictive of nutrition-associated 
complications in different patient groups including cancer patients [109]. In paper III one item 
from the SGA was used. (i.e. the question; “as compared to normal, I would rate my food 
intake during the past month as either unchanged, more than usual or less than usual). Food 
intake reported as less than usual in the SGA was considered as an energy intake less than 
1500 kcal/day according to previous studies [107, 110]. 
24-hour recall
The 24-hour recall method was used in paper II for registration of dietary intake. The 
interview was conducted face-to-face and the patients were asked to remember and report all 
the foods and beverages consumed in the preceding 24 hours. The quantities eaten were 
estimated by the patient and described in household measures as the number of units 
consumed (e.g. cups, glasses, spoons, number of slices, pieces, decilitres). A photographic 
booklet with portion sizes was used. Tables of food portion sizes were used to translate 
household measures to weights [111]. Food intake estimated as <20 kcal/kg per day was 
classified as anorexia [26, 112].
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3.3 Statistics 
The PASW 18 (SPSS Inc., Chicago, II, USA) (Papers I and III) and IBM SPSS statistics v 21 
(Armonk, NY, USA) (Paper II) were used for all statistical analyses. In paper III the software 
program GraphPad Prism (version 6, La Jolla, CA, USA) was used. Sample size calculations 
were not performed in any of the studies partly because of the descriptive study designs and 
partly because of lack of adequate background information to perform such calculations. 
Statistical significance was accepted for P-values <0.05. 
Standard descriptive statistics (percentage, mean, median SD/range etc.) were used in all 
studies. 
Comparison of groups in paper I was tested for significant difference with the independent 
samples t-test when comparing overweight and lean participants, and ANOVA was performed 
when comparing tertiles of body composition and inflammatory markers. In paper II the 
Mann Whitney U test was used for comparison of cytokines and adipokines at study entry vs 
<3 months before death, and the Wilcoxon signed rank test was applied when comparing 
cachectic vs non-cachectic participants. In paper III comparisons between the two 
classifications of cancer cachexia was performed by a 2x2 contingency table and McNemar’s 
test. Fisher’s exact test was used to compare mortality within three months from diagnosis for 
the two cachexia classifications. The significance level was set at P <0.05. 
Univariate linear regression analyses were applied to quantify the relationship between BIA 
and anthropometric measurements of body fat. A stepwise reduction model procedure was 
conducted, where the F-ratio test was used. The variables age and sex were adjusted for to 
avoid confounding effects (paper I).  
Survival was defined as time from the date of a histologically verified diagnosis to the date of 
death (papers II and III), and was analyzed using Kaplan-Meier curves and the log rank test 
(paper III).  
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3.4 Ethical considerations 
The studies in this thesis were approved by the Regional Committee of Medical Health 
Research Ethics South East Norway and by the Norwegian Social Science Data Services, and 
performed in accordance with the Declaration of Helsinki [113]. All study subjects gave 
written informed consent prior to participation.  
In all studies, and particularly so in studies with patients with advanced stage cancer and short 
life expectancy, patient burden must be minimized. It is, however, also considered important 
that research is conducted in these groups. Thus, it is important to optimize symptom 
assessment and reduce respondent burden in frail patients. To comply with this, extra blood 
samples for specific biomarkers (interleukins etc.) were drawn at the same time as routine 
blood samples if possible. The CT scans used for assessment of sarcopenia, were the same as 
those taken for initial diagnosing and staging, and the pancreatic cancer patients were not 
asked to fast. Anthropometric measurements and the 24-hour food recall interviews were 
performed at the same day as other appointments at the OUH to avoid extra traveling.  
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4   Summary of results  
Paper I: Measurements of body fat are associated with markers of 
inflammation, insulin resistance and lipid levels in both overweight and in lean, 
healthy subjects 
A high percentage of body fat in overweight subjects is associated with enhanced levels of 
adipokines, cytokines and risk markers for lifestyle-related disorders. The aim of this cross-
sectional study was to investigate associations between body composition and inflammatory 
markers among healthy individuals in different BMI categories. Anthropometry (waist- and 
hip circumference, WHR and TSF) and fat mass (kg and %), measured by BIA, were 
correlated with inflammatory markers (i.e. IL-6, CRP, IGF-1) and adipokines (i.e. leptin, 
adiponectin, resistin) in 47 healthy overweight adults (BMI 26-49 kg/m²) and 40 lean (BMI 
17-25 kg/m²) adults, matched for age and sex. The main findings were that hip circumference 
was significantly associated with BIA-assessed fat mass (%) in both lean and overweight 
individuals. An increase in hip circumference was associated with higher plasma levels of 
leptin and CRP in both groups. Interestingly, CRP increased with increasing BMI, also in the 
lean group.  
To conclude, an increase in fat percentage was associated with increased levels of 
inflammatory markers (i.e. CRP) and adipokines (i.e. leptin) in overweight persons, but also 
among persons within the normal range of BMI. Hip circumference stood out as a surrogate 
measure for fat mass (%) in subjects within different BMI categories, and may be useful for 
identification of fat percentage in both overweigh and lean individuals. The results may 
indicate that adherence to a healthy lifestyle to prevent a high percentage of body fat is 
important for both lean and overweight people in order to limit low-grade inflammation in the 
body, and thus reduce the risk for overweight-related chronic diseases.  
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Paper II: Alterations in inflammatory biomarkers, body composition and food 
intake in pancreatic cancer patients with cachexia: a prospective study  
Chronic inflammation is proposed as an underlying biological mechanism for development of 
cancer cachexia, but the levels of inflammatory markers and associations to cancer cachexia 
have not been established. The aim of the study was to study changes in the levels of 
inflammatory markers, FFM, fat mass and energy intake in an unselected cohort of pancreatic 
cancer patients with or without cachexia, as they approached the terminal stage of their 
disease.  
As there are no reference values for inflammatory markers, biomarkers and measures of FFM 
and fat mass from healthy lean individuals were used as reference material. Twenty patients 
with newly diagnosed inoperable pancreatic cancer were included after being included in the 
pancreatic project. Cachexia was classified according to the consensus definition of cancer 
cachexia and sarcopenia was assessed as MUAC <18 cm² (female), <32 cm² (men). FFM, fat 
mass, cytokines, CRP and adipokines, and food intake were measured prospectively from 
inclusion and up to a maximum one year. It was shown that at inclusion, eleven (55%) 
patients were classified as cachectic, and there were no significant differences in CRP, 
cytokines and adipokines, FFM, fat mass and energy intake between the cachectic and non-
cachectic patients. During the disease trajectory, FFM and fat mass decreased slightly. Most 
inflammatory markers increased, however, INF-γ remained stable, while leptin and IGF-1 was 
reduced. All changes were insignificant except for the elevation of IL-10 levels. 
To conclude, patients with advanced pancreatic cancer experience an ongoing inflammation, 
and at the same time they lose fat mass and FFM. However, patients classified as cachectic 
immediately after diagnosis did not have higher levels of inflammatory markers than patients 
classified as non-cachectic. Inflammation in the cancer patients may be caused by the 
presence of the tumor and may eventually cause symptoms similar to cachexia. This makes it
difficult to distinguish between symptoms caused by the cancer and symptoms caused by 
cachexia. Moreover, increased inflammation may stimulate fat and muscle mass depletion. 
For this reason, an optimization of cancer treatment is essential in pancreatic cancer patients.  
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Paper III: Comparing two classifications of cancer cachexia and their 
association with survival in patients with unresected pancreatic cancer 
Cancer cachexia is characterized by reduced weight and muscle mass, poor treatment 
tolerance and short survival. The two most common classifications of the condition have been 
the 3-factor classification requiring presence of two or more of the following three factors; 
weight loss ≥10%, food intake ≤1500 kcal/d, and CRP ≥10 mg/l, and the consensus 
classification requiring either weight loss >5% the past 6 months, or BMI <20 kg/m² or 
sarcopenia, together with ongoing weight loss >2%. Thus, one definition includes 
inflammation as a criterion, while the other definition includes reduced muscle mass as one of 
the criteria. The aim of the study was to examine the consistency between the two 
classifications in defining patients as cachectic or not, and to investigate the association with 
survival in a palliative cohort of unresected pancreatic cancer patients. Forty-five patients 
were included. Sarcopenia was assessed by lumbar skeletal muscle index determined by CT-
imaging (men <55 cm²/m² and women <39 cm²/m²). Values for height, weight, CRP and 
survival were extracted from the pancreas data base and the patients’ medical records. Food 
intake was assessed by SGA (anorexia was determined by self-reported food intake less than 
usual). It was found that the agreement for cachexia and non-cachexia was 78% across the 
two classifications. Survival was significantly shorter in cachectic patients compared to non-
cachectic patients according to both classifications. However, the difference in survival 
between cachectic and non-cachectic patients according to the consensus classification was 
significant only after dividing the non-cachectic group into a pre-cachectic and a non-
cachectic group (i.e. separating the patients with high CRP and low food intake from the non-
cachectic group).  
To conclude, the two classifications showed good overall agreement in defining cachectic 
patients in this cohort with pancreatic cancer, and cachexia was associated with poorer 
survival according to both. Our findings suggest that the classification including systemic 
inflammation (i.e. CRP >10 mg/l) as a criterion was a better predictor of survival. Patients 
with weight loss, reduced energy-intake, sarcopenia and indications of metabolic change (i.e. 
CRP >8 mg/l) had the poorest survival. Thus, clinical interventions should be directed to 
optimize these known risk factors. 
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5 Discussion 
In this thesis, the association between inflammation and body composition was investigated in 
a healthy overweight and lean population and in a cohort of pancreatic cancer patients with or 
without cachexia.  
5.1 Methodological considerations 
5.1.1 Study designs 
In the field of preventive medicine and palliative care, observational studies are important to 
e.g. generate hypotheses or build evidence for identifying best hospital practices. The method
involves the direct observation of individuals in their natural setting, thus “exposures” or 
interventions on subjects are determined by individual preferences, hospital practice patterns 
or policy decisions [114, 115]. 
Cross-sectional studies 
A cross-sectional study is an observational study in which exposure and outcome are 
determined simultaneously for each subject, often described as taking a snapshot of a group of 
individuals. The primary intention with this study design is screening, hypothesis generating 
and to estimate prevalence [115]. The study design has been used to understand the 
prevalence of various conditions or associations of different characteristics: e.g. visceral 
obesity and life style related disorders [115, 116]. However, one of the problems with cross-
sectional studies is that because the exposure and outcome are measured simultaneously, there 
is no evidence that the exposure (e.g. fat mass) causes the outcome (e.g. CRP: paper I). Thus, 
causal inferences cannot be drawn. However, if the exposure is a characteristic such as gender 
and the outcome has developed over time the temporal association between the exposure (e.g. 
male) and outcome (e.g. FFM: paper I) is more convincing. Otherwise, if the exposure is not 
an inherited trait, causality is unclear [115, 117]. In addition, cross-sectional studies provide 
only an instant picture of a situation and the result may be different at another point in time. 
The marker for systemic inflammation, CRP may for example fluctuate and can be elevated 
for reasons other than elevated fat mass or cachexia [36]. Another problem with cross-
sectional studies is that it evaluates prevalence rather than incidence of an outcome, and thus 
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excludes people who develop the outcome (e.g. cardiovascular disease) but die before study 
entry. Thus, there is a bias toward including people with better survivorship in the study, for 
example metabolically healthy obese individuals, which may cause a healthy adherer effect 
[118]. Moreover, it is important to rule out alternative explanations for the study results (e.g. 
exercise or diet) [115]. Nevertheless, cross-sectional studies can provide new information 
concerning associations between fat mass and lean mass and inflammatory or clinical 
markers, which we aimed for in study I.  
Cross-sectional studies are the most frequently applied study design in palliative care 
research, supplying much of our knowledge about cancer cachexia. However, cross-sectional 
studies should preferably be followed by longitudinal studies in order to confirm hypotheses 
generated in the former [117].  
Cohort studies 
In a cohort study, a study population is selected, then it is determined who are exposed or not 
exposed to a factor and then the subsequent development is evaluated over time. The studies 
can be either retrospective or prospective [115] and study II (paper II and III) has a 
prospective design. In paper II, patients with advanced pancreatic cancer were selected (i.e. 
exposed), and compared to a reference population (i.e. not exposed). Energy intake, body 
composition and inflammatory markers were observed from study entry and close to death. In 
this paper, we also investigated levels of inflammatory markers in patients defined as 
cachectic (i.e. exposed) vs those defined as non- cachectic (i.e. not exposed). In paper III, the 
same study population was observed. Information was obtained to determine who were 
cachectic (i.e. exposed) and who were not cachectic (i.e. not exposed), and the prevalence of 
the condition was associated with survival in the cachectic vs. the non-cachectic patients 
[115]. The problem that may arise when classifying patients as cachectic or non-cachectic 
according to the consensus classification, is that some of the patients who are classified as 
cachectic at study entry respond to chemotherapy or other treatment and thus gain weight, 
increase FFM or skeletal muscle mass. These patients may be classified as non-cachectic 
during the disease course. Other patients may be classified as non-cachectic at study entry but 
lose weight, FFM or skeletal muscle mass during the disease course and may be defined as 
cachectic later in the disease trajectory. Appetite and CRP may also change during this time 
interval. It has been shown that cachexia has a significant impact in terms of morbidity and 
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mortality [119]. However, since the prevalence and incidence of cachexia may vary from 
diagnosis until the time of death, it is challenging to determine the impact of cachexia on 
morbidity and mortality in patients who are receiving anti-cancer treatment. The incidence of 
the condition is normally assessed at diagnosis or study entry; however, patients should be 
monitored several times during a follow up. 
There are three categories of systematic errors related to observational studies: selection bias, 
information bias and confounding. Selection bias may affect the extent to which one can 
generalize from people who were included in the study to people in general (i.e. external 
validity), and information bias and confounding cannot rule out the possibility that external 
variables may have influenced the results (i.e. internal validity) [120, 121]. 
5.1.2 Study samples, strengths and weaknesses 
Participants in paper I were selected through advertisements in newspapers and mass media in 
the surroundings of Oslo and Akershus in the eastern part of Norway. The strength of this 
approach is that this was an efficient way to recruit and evaluate a large sample of individuals 
in a short time period. The use of specific inclusion and exclusion criteria when recruiting the 
participants, may limit the possibility of generalizing the results to a broader population. The 
reason for this is that the participants in paper I did not necessarily represent the general 
population between 30 and 70 years in this area. People who volunteer to participate in health 
surveys tend to be more health conscious and better educated than the rest of the population, 
thereby introducing a selection bias in the direction of a healthy adherer effect [118]. This 
may reduce the external validity of the results. The healthy volunteers in paper I were 
collected in order to investigate the relationship between inflammation and body composition 
in individuals with different BMI in a healthy population, but also to serve as a reference 
population in paper II. However, matching by age and sex was not possible as the healthy 
volunteers were younger than the pancreatic cancer patients with a median age of 53 and 48 
years in the healthy men and women respectively, relative to 67.5 years among the pancreatic 
cancer patients. There was also an uneven sex distribution in the two groups, i.e. the reference 
group included 35% women while there were 25% females in the pancreatic cancer group. 
Notably, some of the variables reported in paper II, such as adipokines can be effected by age; 
leptin may be reduced and adiponectin elevated in elderly people [122]. Therefore, the 
observed differences in adipokines may not only be because of the cancer.  
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In paper II, inoperable pancreatic cancer patients were recruited from an out-patient palliative 
unit. The strength of this approach is that one can study disease progression and the natural 
development of the outcomes [115]. However, there are several issues to consider when 
evaluating these studies. During the recruitment period, only 20 patients were included in the 
study, thus we have a small sample size in paper II. Patients were not included or not willing 
to participate for several reasons; i.e. some were too tired to participate or died before 
inclusion, while others were treated at their local hospitals and they were not followed at 
OUH. A small number was included in the study but dropped out during the follow-up. In 
longitudinal studies, missing data is inevitable, and in the palliative care setting missing data 
is often attributed to worse health status [123, 124]. This means that the data is not missing at 
random, and may thus introduce a bias: a healthy adherer affect [115, 118]. A third source of 
missing data is that patients do not answer all the questions in a questionnaire, for example 
“pre-illness weight” (paper II). Unless this applies to specifically sensitive questions, 
occasionally missing data is most often at random, and is of lesser importance regarding 
generalizability. However, as in this case, the missing data can result in biased estimates and 
loss of statistical power due the small sample size. The best way to deal with this statistically 
is to impute the available longitudinal data of that person [124]. This procedure was done in 
paper II, with the first observation carried backward method.  
In paper III only patients with CT scans taken 30 days prior to and 10 days after diagnosis 
were included, and for that reason a large number of patients were excluded in this study. In 
spite of that, the mean survival after diagnosis of the excluded and included patients was 
similar, 39 and 37 weeks respectively. This means that a systematic difference and a selection 
bias between the included and excluded group is unlikely, and that the sample is 
representative for this particular population. Although the statistical power is reduced due to 
the small sample size, the strength of the study is that the data set is complete, with no 
missing values. This is rarely achieved in palliative care research [123]. 
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5.1.3 Validity of methods 
Food intake, SGA and 24-hour recall 
The question from the SGA that evaluates nutritional intake is; “as compared to normal, I 
would rate my food intake during the past month as either unchanged, more than usual or less 
than usual”. The answer to this question has not been fully validated against prospective 
records of energy intake. A study of 22 patients however, found that self-reported reduced 
food intake from the Patient-Generated SGA (i.e. PG-SGA) was associated with reduced 
calorie intake Furthermore, when a patient claimed to eat less than usual, energy intake was 
evaluated to be <1500 kcal/d [110]. In paper III we therefore evaluated the answer from SGA 
of energy intake “less than usual” to be <1500 kcal/day; and used this value to classify 
anorexia in paper III. This estimation is in accordance with Fearon et al. [44], who suggests 
that patient’s own estimate of their overall food intake in relation to their normal food intake 
could be used as an assessment of a patients food intake [44]. However, although a patient 
reports to eat less or more than usual, this may not correspond to actual energy intake, due to 
an underestimation or an overestimation of own food intake, respectively. 
The 24-hour interview is often structured, using specific probes, which is a tecqnick that helps 
the respondent in remembering all the foods and drinks consumed in the preceding day [125]. 
In paper II probing was especially useful in collecting necessary details, such as how foods 
were prepared (e.g. butter on toast), and foods not originally reported (e.g. snacks or 
beverages).  However, the patients may not have reported their food intake accurately due to 
lack of knowledge, memory or the specific interview situation. The patients may also have
underestimated or overestimated their own food intake.   
Methods for measurement of body composition in healthy individuals and in 
cancer patients 
The BIA is commonly used in clinical practice where quick evaluations of nutritional status 
and measurements of FFM and fat mass are needed [126]. The reliability of BIA depends on 
the use of body composition prediction equations that are adapted to the study subjects and 
based on the inclusion of various parameters (i.e. weight, height, sex, age, race) [127]. 
However, the equations are validated in heathy populations and may as such be influenced by 
disease [126]. This also means that body composition measurements may be imprecise in the 
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presence of abnormal distribution of body compartments (e.g. ascites, dialysis, lipodystrophy) 
or in persons with extreme weights (e.g. cachexia, severe obesity) [127]. In this thesis, BIA 
was used on overweight individuals (paper I) and cancer patients (paper II). In order to 
standardize the measurements, all participants in paper I were asked to refrain from alcohol 
use and heavy exercise 24 hours before measurements, and all measurements were performed 
after a minimum of 12 hours fasting and after urination. However, these standardizations were 
not requested in the cancer patients due to the severity of the disease. This difference may 
have influenced the results as some patients may had just eaten while others had not, which 
may have resulted in increased FFM estimates from the BIA. Nevertheless, BIA is often used 
in clinical settings and for research purposes and is feasible on a population level [90, 102]. 
The method was therefor considered a suitable method for the purpose of our study. 
Magnetic resonance imaging (MRI), DEXA and CT scans are commonly used to measure 
muscle mass in cancer patients [128]. In cancer patients, CT scans are used for initial 
diagnosis and to monitor disease progression [23]. These scans are often stored and accessible 
in a digital format which makes it possible to evaluate the patient’s body composition during 
disease progression. In our cohort (paper III), we experienced that although CT scans were 
repeatedly conducted, the time span between CT scans were not the same for all patients. 
Many patients were therefore excluded due to the lack of CT scans in the time span 30 days 
before or 10 after diagnosis. In several studies, CT scans completed within 30 days of the 
patients’ initial visits are considered to accurately measure muscle mass at presentation [129]. 
Sarcopenia has been associated with functional impairment, disability and reduced survival 
[130, 131], and is classified as reduced quantity of skeletal muscle mass or more than two 
standard deviations below the muscle mass typical of healthy adults [132]. In paper III, 
sarcopenia was assessed by CT images, but in paper II CT scans were not available from all 
participants within the requested time span. Hence, we had to assess sarcopenia by mid-upper-
arm muscle area (MUAMA), as suggested in the latest consensus definition of cancer 
cachexia [44]. The consistency of CT images and MUAMA in their ability to assess 
sarcopenia, was not evaluated in this thesis. 
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Statistics and confounders  
A confounder is a characteristic which is associated with the exposure in the population and 
with the outcome, and not in the causal pathway between the exposure and outcome [120]. A 
confounder may under- or overestimate the association that is investigated, and may even 
change the direction of the effect on the outcome measures. Confounders may be handled by 
matching, by restriction (i.e. exclusion criteria), or by adjustment in the statistical analysis. In 
paper I, specific inclusion and exclusion criteria were used. We also matched the overweight 
and lean individuals for age and sex to avoid the confounding effect by these two factors on 
variables, such as adipokines, as it is known that age and sex influence these markers [122]. 
Matching does not completely control for confounders, thus the variables were also adjusted 
for possible effects of confounders by logistic regression. We were not able to do a matching 
between the cancer group and the healthy reference population in paper II. Since no reference 
values for inflammation markers exist, the comparison of inflammatory markers in these two 
groups gives us an indication of the magnitude of elevation or reduction in inflammatory 
markers in the cancer group. However, we did not adjust for age and sex in these 
comparisons, thus these variables may act as confounding factors in paper II.  
5.2 General discussion  
5.2.1 Inflammation and body composition  
Adipokines and fat mass in healthy individuals 
Adipose tissue secretes adipokines (i.e. leptin and adiponectin) that play a role in overweight-
related disorders [86]. In paper I, it was shown that overweight subjects had significantly 
higher levels of leptin, compared to the lean subjects, and that the levels of adiponectin were 
significantly lower in the overweight group compared to the lean group. The findings are 
consistent with previous studies [92]. It was also shown that leptin levels increased 
significantly across tertiles of fat percent in the overweight and the lean group, respectively, 
and that women had significantly higher levels of leptin than men. These results are as 
expected, as leptin is secreted by fat mass [86] and overweight individuals have significantly 
more body fat mass (kg and %) than lean individuals, and women have significantly more 
body fat mass (kg and %) than men. Furthermore, although there is an inverse relationship 
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between adiponectin and adiposity [133], adiponectin levels increased significantly from low 
to high fat percent in both overweight and lean individuals, and was higher in women than in 
men (paper I). These findings may be explained by the protective role of adiponectin and its 
attempt to maintain an anti-inflammatory profile in plasma although fat percent increased 
[133]. In lean, the fat percent measured by BIA was associated with hip circumference and 
TSF, suggesting that the fat is located subcutaneously in lean individuals. Furthermore, in the 
lean we found that an increase in hip circumference was significantly associated with higher 
levels of leptin. Since leptin is normally secreted by subcutaneous adipose tissue [122] these 
results were as expected. 
Inflammatory markers and fat mass in healthy individuals 
Adipose tissue may be an underlying source of cytokines, causing CRP production in the liver 
[4, 5]. The overweight women in our study had the highest levels of whole body fat mass (kg 
and %), and also the highest circulating concentration of CRP. The concentration of CRP 
increased across all tertiles of BMI, and interestingly, it increased significantly in the lean 
group. This confirms findings from other studies of an association between fat mass and 
inflammation in lean individuals [134]. Leptin induces the production of for example reactive 
oxygen species [135], and it has been shown that lower-body fat mass (i.e. subcutaneous fat) 
plays an important role in systemic oxidative stress, which again may induce a dysregulation 
of the production of adipokines and inflammation, also in lean subjects [136]. This may 
explain the increasing levels of inflammation when going from low to high BMI.  
Inflammatory markers in relation to body composition in pancreatic cancer 
patients  
Adipokines and cytokines regulate each other. The leptin receptor belongs to the class 1 
cytokine receptor family and leptin itself has pro-inflammatory properties as it has structural 
similarities with IL-6 [76]. Moreover, leptin also stimulates the production of IL-6 and TNF-α 
[86]. The anti-inflammatory effect of adiponectin is by stimulating the production of IL-10 
and inhibiting the production of TNF-α. However although IL-10 is considered anti-
inflammatory, increased IL-10 is associated with weight loss and worsened prognosis in 
chronic disease [137].  
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Plasma leptin level is proportional to fat mass and has been related to loss of body fat loss 
[138]. In our study, leptin levels correlated significantly with fat mass in the healthy adults as 
well as fat mass index in pancreatic cancer patients (papers I and II). Furthermore, loss of fat 
mass was accompanied by a decline in leptin levels (paper II, table II).The concentrations of 
leptin and IL-6 are closely linked since leptin stimulated the production of IL-6 [86, 139], and 
thus, both leptin and IL-6 were positively correlated to fat mass (papers I and II) and 
negatively correlated to FFM index in healthy individuals. In contrary, this correlation was 
opposite in the cancer patients (paper II). In diseases with chronic inflammatory conditions, 
inflammation causes a reduction in leptin levels [91], which may be part of the reason for the 
reduced circulating concentration of leptin in pancreatic cancer patients (paper II). Thus, the 
decline in leptin levels may be caused by both reduced fat mass and increased inflammation. 
Furthermore, it has been shown that leptin levels decrease with age, in women [122]. Our 
patients had a median age of 67.5 years, while median age of the reference population was 
50.5 years i.e. about 17 years younger, thus age may, at least in part, explain some of the 
changes in the levels of leptin and other adipokines in our study.  
Whereas leptin levels were low and continued to decline throughout the observational period, 
the levels of adiponectin were higher among the patients than in the healthy individuals at 
study entry, and concentration of adiponectin continued to increase towards death. This is in 
accordance with results obtained from a case control study in patients with pancreatic cancer 
[140]. High levels of adiponectin in pancreatic cancer may be part of a compensatory 
response to insulin resistance or weight loss which often occurs during the course of the 
disease [140]. High levels of adiponectin has also been shown to promote pancreatic cancer 
cell growth in pancreatic cancer patients, however the association between circulating 
adiponectin and pancreatic cancer remain controversial and require further exploration [141].  
Tumor microenvironment and inflammation 
Tumors and the tumor microenvironment may also cause a dysregulation of the production of 
cytokines, which stimulate an activation of white blood cells and other immune cells, 
resulting in the release IL-6 and TNF-α [11, 142]. Previous studies have shown increased 
levels of IL-6 and TNF-α in cancer patients losing weight [34, 77]. This was confirmed in 
paper II, as the patient group had higher levels of circulating IL-6 and TNF-α than the 
reference population at study entry, and the levels increased during the disease course. In 
paper II, the levels of IL-6 and TNF-α correlated positively with FFM index in the cancer 
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group, but negatively in the healthy adults. Considering an elevated cytokine production in the 
patient group, this may explain correlations that were the opposite of that in healthy adults. In 
the presence of a tumor, the body reacts with a systemic inflammatory response in the brain, 
liver and skeletal muscle, which leads to symptoms like anorexia, reduced food intake, fatigue 
and pain as well as altered metabolism. These symptoms may again lead to weight loss, poor 
performance status and reduced survival. Interestingly, these symptoms are similar to 
symptoms of cachexia [35] and may arise from the tumor itself [142] Thus, it is essential to 
treat the underlying cause; the cancer. However, in patients with advanced pancreatic cancer, 
there is no cure, thus palliative treatment including palliative chemotherapy is important to 
improve QoL, relieve symptoms and prolong life [22].  
Systemic inflammation driven by pro-inflammatory cytokines is assumed to play an important 
role in the development of cancer cachexia [37, 142]. The acute phase response is a sign of 
systemic inflammation and is clinically often measured by increased CRP and decreased 
albumin levels [34, 142]. Paper II shows an insignificant increase in CRP and a significant 
decrease in albumin levels, indicating an inflammatory response in the cancer patients [34, 
77]. It has been suggested that there is a local cytokine production in peripheral blood 
mononuclear cells and in adipose tissue, especially SAT, which may have systemic effects on 
metabolism and weight loss in cancer patients [31, 143]. Plasma levels of inflammatory 
markers were not significantly different in the cachectic versus the non-cachectic patients, as 
defined with the consensus definition. One explanation may be that the magnitude of local 
inflammation is not detectable in plasma [31]. Moreover, in patients defined as non-cachectic 
because they have no weight loss or sarcopenia, local inflammation can be an underlying 
cause of FFM depletion due to protein degradation or proteolysis [22]. Thus, these patients 
may develop cachexia later on in the disease trajectory. 
Taken together, inflammation in cancer patients may arise from the tumor and may cause 
changes in the body composition of the patients. This notion is in line with previous 
assumptions (Figure 3) [22]. 
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Figure 3: Mechanisms of the tumor microenvironment in pancreatic cancer patients 
Modified from Tan et al. [22] 
5.2.2 Body composition in pancreatic cancer patients.
Depletion of fat mass 
We demonstrated that pancreatic cancer patients lose both muscle and fat during the disease 
trajectory (paper II), which confirms findings from a previous study in pancreatic cancer 
patients [144]. At study entry, the cancer group had less fat mass (FMI and fat %) than the 
reference group. Furthermore, fat mass was lost during the disease trajectory. A prospective 
study in cancer patients referred for palliative care showed that decreased body weight was 
explained by loss of fat mass [138]. Others claim that adipose tissue wasting can be detected 
even before changes in food consumption [31]. It has also been demonstrated that fat mass is 
lost more rapidly than lean tissue in cancer patients losing weight [39], and that the loss of fat 
mass, both VAT and SAT precedes the loss of skeletal muscle mass [90]. These findings may 
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explain why weight losing cancer patients have lower adipose tissue mass than weight stable 
cancer patients and healthy reference populations [90, 145], as in our study (paper II).  
Depletion of fat-free mass 
The underlying mechanisms of the loss of skeletal muscle have been suggested to be catabolic 
hormones such as glucocorticoids (which was not measured in our study) and chronic 
inflammation, but also inhibition of anabolic pathways, such as the ones controlled by IGF-1 
[144, 146, 147]. Furthermore, in a longitudinal study in cancer patients, IGF-1 was predicted 
by lean body mass [138]. In line with this, we found lower IGF-1 levels in the patients than in 
the reference group, and the levels continued to decline, indicating loss of anabolic factors in 
the cancer patients. Loss of this anabolic-stimulating hormone may contribute to the 
progression of muscle atrophy, which is a characteristic feature in cancer cachexia, but also in 
aging and sarcopenia [148, 149]. In addition, low IGF-1 is associated with reduced protein 
intake. In paper II, the patients had lower protein intake than recommended for this group 
[150]. Furthermore, poor nutritional status has been connected to reduced IGF-1 levels in 
cancer patients [149], thus negative energy balance and fat loss may lead to reduced 
production of IGF-1 and anabolic stimuli.  
Compared to the healthy reference group, the patients had lower lean body mass (FFMI and 
MUAMA), and experienced a loss of both FFMI and MUAMA during the disease trajectory. 
It has been shown that FFM is lost from arm tissue while that of leg and trunk compartments 
increase [138, 151]. These findings are partly confirmed in our study (paper II), where arm 
muscle measured by MUAMA was reduced. FFM was also slightly reduced. Four patients 
gained weight throughout the disease course, whereas tree of these gained FFM (data not 
shown). However, it has been speculated that this may be due to an increase in the FFM in 
internal organs such as the liver and spleen [151], rather than to an increase in skeletal muscle 
mass. Another possibility is attributed to BIAs limited ability to provide a direct estimate of 
FFM in cancer patients. MUAMA is perhaps a better indicator of muscle mass changes 
because it is not affected by body water. 
Collectively, fat accumulation at the time of diagnosis may contribute to cancer progression 
[90]. The pro-inflammatory cytokines IL-1β, TNF-α and IL-6 produced by the tumor or host 
tissue due to tumor presence, lead to both local and systemic inflammation and may 
contribute to fat mass depletion due to for example increased lipolysis, and FFM depletion 
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due to proteolysis [22, 31]. Reduced energy intake and leptin levels may inhibit IGF-1 
production in pancreatic cancer patients. Consequently, it leads to a reduction of anabolic 
stimuli and loss of skeletal muscle mass. The anthropometric measure, MUAMA seems to be 
a good measurement of changes in muscle mass in weight losing pancreatic cancer patients.  
Two of the processes taking place during the progression of pancreatic cancer are an increase 
in inflammatory markers and the loss of body mass, both FFM and fat mass. The underlying 
causes of these two processes are not fully elucidated in this thesis; however, there are 
indications that the processes may be initiated by the presence of the tumor itself. Although 
these changes in inflammatory markers and body composition were observed, only IL-10 
increased significantly throughout the disease course. The reason for the lack of a significant 
increase in inflammatory markers may be the small sample size in this study. However, 
enhanced IL-10 production is perhaps an indication of the severity of the disease, or it could 
be an indication of a disruption of anti-inflammatory mechanisms [34, 65].  
5.2.3 Cachexia definitions and diagnostic criteria 
Consistencies between two central definitions of cancer cachexia in their 
ability to predict prevalence and survival time  
In paper II we found a good overall agreement between the latest consensus definition, which 
includes reduced muscle mass [44] as a criterion, and the 3-factor definition, which includes 
systemic inflammation (i.e. CRP >10 mg/l) [37]. Both classifications of cachexia predicted 
poorer survival when patients were classified at inclusion. However, the consensus definition 
only predicted significantly reduced survival in the patients when the non-cachectic patients 
were divided into a pre-cachectic and a non-cachectic group (paper III). Patients with no 
weight loss or signs of anorexia and metabolic change (i.e. CRP >8 mg/l) had longer survival 
than pre-cachectic and cachectic patients. Similarly, a study from 2010 [152] demonstrated 
that cancer patients with no weight loss and no anorexia had significantly longer survival than 
patients with either anorexia or weight loss or the combination of the two. These findings may 
help us in the further characterization of cachexia.  
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Skeletal muscle mass 
The common focus of the definitions proposed to classify cachexia is on the loss of skeletal 
muscle mass due to negative protein balance and the resultant loss of physical function [25, 
153]. Skeletal muscle mass depletion and systemic inflammation (CRP >10mg/l) are strong 
predictors of overall survival and prognosis [104, 129]. In a study of cancer patients referred 
to a palliative care program, it was shown that patients with systemic inflammation had less 
muscle mass than patients without systemic inflammation and that muscle mass was lost at an 
accelerated pace during the disease trajectory. In addition they had shorter survival than 
patients without systemic inflammation [80]. It was also found that patients with pancreatic 
cancer had less muscle mass compared to patients with biliary tract- or colorectal cancer in 
the end of life [80]. The 3-factor definition was developed in pancreatic cancer patients and 
may therefore be better suited for detecting cachexia in this patient group only. However, 
validation of this definition in clinical studies lacks. We used the consensus definition to 
classify the patients at diagnosis (paper II); however, it is difficult to use this definition 
throughout the disease trajectory because one of the criteria is weight loss. Some patients 
responding to chemotherapy may actually maintain and/or gain muscle mass during such 
therapy [154, 155]. Moreover, the patients with cachexia are heterogeneous as some patients 
lose weight rapidly while others remain weight stable or gain weight [151, 156]. 
Consequently, a patient defined as cachectic at diagnosis, may gain muscle mass and thus 
may be defined as non-cachectic during the disease trajectory. Thus, the weight loss is not 
completely irreversible prior to reaching its refractory phase [50] and the focus of initiating 
anti-cachectic treatment, should be at the time of cancer diagnosis when the patient is in the 
pre-cachectic or the cachectic phase [157].  
Other diagnostic criteria  
Although cytokines are known to be the driving force behind cachexia, and as has been 
detected in previous studies [158], we did not find any differences in inflammatory markers 
between cachexia and non-cachexia, classified by the 2011 consensus definition of cancer 
cachexia (paper II). The reason for the discrepancy between our study and previous studies 
may be that the latter did not define cachexia by sarcopenia and weight loss as we did in paper 
II, but by weight loss [42] or low BMI alone [158]. According to the consensus definition, 
only one out of three classification criteria should be met. Thus patients may be assigned to a 
cancer cachexia group purely on the basis of weight loss >5% in the past 6 months, or BMI 
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<20 kg/m² and weight loss >2% (whereas the time frame of weight loss is not specified) [44, 
159]. As the majority of patients with advanced cancer have lost weight prior to diagnosis, 
patients may be classified as cachectic on the basis of BMI <20 kg/m² and weight loss >2% in 
an unlimited amount of time. The rate of weight loss within a specified timeframe is 
considered important [144, 159], and should therefore be specified in the diagnosis. Although 
CRP assessment is favored, the cut-off of inflammation is also not specified in the consensus 
definition. In paper II we used a cut off of 8 mg/l as in a previous study [52]. The reference of 
this cut-off is not given other than that it was assessed by experts. The prevalence of cachexia 
may differ according to which CRP cut-offs and to which criteria of the cachexia 
classifications that are used: while using the first criterion of the consensus classification (i.e. 
weight loss >5% during the last 6 months), Bozzeti et al. found that 60% of the patients were 
defined as cachectic. When they used the second criterion (i.e. weight loss 2% or 5% in 
combination with BMI <20 kg/m²) the prevalence was only 36%. This means that the 
classification identifies different groups of patients as cachectic, and that there is still a need 
for an agreed and validated classification of cancer cachexia [160]. A further validation in 
clinical studies is important. Martin et al [161] showed that patients with involuntary weight 
loss in addition to loss of muscle mass and low muscle attenuation (i.e. fat infiltration), have 
reduced survival regardless of overall body weight.  
Studies have shown that patients with weight loss experience more symptoms like loss of 
appetite. Along with early satiety, loss of appetite may be responsible for a reduced dietary 
intake [25]. Considering pre-cachexia, no concrete directions in the consensus classification 
are given to how anorexia should be measured. In our study, energy intake was assessed 
(papers II and III). Patients who reported that they ate less than usual (paper II) or who had an 
energy intake <1500 kcal/d (paper III) were assumed to have anorexia. Mean dietary intake 
was measured to 1449 kcal/d based on a 24-hour recall (paper II). Although the general 
energy intake was low, patient perception of their own food intake was not associated with the 
estimated energy intakes (data not shown). Both energy and protein intake were higher in 
cachectic than in non-cachectic patients in our study (paper II). This is possibly because some 
patients who experience appetite and/or weight loss still manage to eat to avoid low food 
intake and weight loss [162]. Additionally, the focus of care in these patients is palliative and 
catabolic agents such as the corticosteroids may be selected to obtain a brief appetite spurt 
[156], however, weight gain is mainly caused by increases in water and fat [50]. 
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5.2.4 Clinical considerations 
Healthy adults 
To keep a stable weight and to engage in physical activity for >30 min/day is important in 
both lean and overweight individuals, and may be beneficial in order to stay metabolically 
healthy and to avoid life style related chronic disorders [163]. The anthropometric 
measurements TSF and hip circumference may be appropriate in order to measure fat 
accumulation in lean individuals, and waist and hip circumference are perhaps more 
appropriate in overweight individuals.  
Pancreatic cancer patients 
In our study weight loss and sarcopenia (consensus classification), and reduced food intake 
and increased CRP (3-factor classification) were most frequently measured (paper III). Since 
these factors (i.e. weight loss, reduced food intake, systemic inflammation and sarcopenia) are 
frequently observed [42, 152, 161, 162], clinicians should be watchful to these complaints. 
In cases of nutritional risk (i.e. weight loss or risk of malnutrition), early involvement of 
dieticians and nutrition assessment programs is essential. Both appetite loss and food intake 
should be assessed in this process [22, 162]. Nutritional support involves dietary advice and 
oral nutritional supplementation, which can significantly increase oral caloric and protein 
intake, and have had positive effects on weight and appetite, respectively [22]. It is estimated 
that energy intake should increase by 300-400 kcal per day and the protein intake by up to 
50%. However, these nutritional goals are difficult to achieve in cancer patients receiving 
anti-cancer therapy. In these situations, parenteral nutrition can be one way of reaching the 
nutritional goals and may have led to prolonged survival [50]. Although specialized 
nutritional supplements are associated with weight stabilization by partly reversing fat loss, 
the metabolic changes preclude reversal of muscle wasting [50]. Thus, the nutritional 
response is limited. Therefore, it is now widely recognized that cachexia is best managed with 
a multimodal approach, including nutrition, physical activity and anti-inflammatory 
medication [22, 164].  
Physical activity may induce muscle anabolism and thus resistant exercise may antagonize 
muscle atrophy. It has been shown that exercise is feasible in cancer patients and that it may 
improve physical performance [50]. In terms of targeting the inflammatory response, anti-
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inflammatory agents such as NSAIDs, Thalidomide and omega-3 fatty acids have been 
investigated. NSAIDS evidently decrease the production and release of acute phase proteins 
and pro-inflammatory cytokines. However, Thalidomide is teratogenic and associated with 
potentially adverse effects and omega-3 fatty acids have shown conflicting results [22, 50], 
thus further investigation is warranted.  
Taken together our findings in paper II and III support previous suggestions of a basic 
standardized approach to cachexia treatment. First, to target the tumor by anti-neoplastic 
therapy; second, to target systemic inflammation by anti-inflammatory drugs or nutrients; 
third, to target all secondary causes of cachexia, such as pain or nausea; fourth, to optimize 
energy intake by nutritional support, and finally physical activity must be recommended and 
adequate support given [50]. Anti-cachexia therapy should be initiated in a pre-cachectic 
phase, during palliative cancer therapy (i.e. supportive oncology), when the patients is 
responsive to treatment rather than in the refractory phase [50, 157], emphasizing that early 
recognition of cancer cachexia is essential.  
Moreover, since fat mass depletion reflects negative energy balance and may occur prior to 
the detection of appetite loss, TSF may be an adequate method to estimate fat mass depletion 
in pancreatic cancer patients and may be one of the methods included in the early detection of 
cancer cachexia. Furthermore, MUAC and MUAMA may be methods for estimation of early 
lean tissue depletion [35]. 
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6 Further perspectives  
Targets relevant to future treatment of cachexia may be either by antagonizing key mediators 
of systemic inflammation, such as IL-6 and TNF-α, or by blocking catabolic pathways such as 
myostatin and activin [22, 164]. Alternative targets include pathways in the central nervous 
system that control appetite [164].  
Nutritional management of cancer cachexia is limited since none of the available therapies has 
shown long-lasting effects on weight stabilization and improvement in survival [22, 165]. 
Moreover, there is a lack of knowledge about clinical nutrition within oncology, partly due to 
little evidence-based therapy [50]. However, since it is not possible to increase or stabilize 
weight if the patients’ nutritional needs are not met; nutritional intervention is an important 
part of the treatment of cancer cachexia [165]. This in turn makes it necessary to require a 
greater awareness about nutrition and the increased nutritional needs in patients with 
advanced cancer among health care professionals. The future management of cachexia in 
pancreatic cancer patients will likely involve a multimodal approach with nutritional support 
combined with treatment aiming to modify inflammation and catabolism, in addition to 
palliative chemotherapy [165]. The balance between improved survival and maintenance of 
QoL is a key feature in the management of cachexia, thus outcomes such as weight 
stabilization, physical function and improved QoL are important aims in the foreseeable 
future [164].   
 
56 
7 Conclusions   
The overall aim of this thesis was to gain more knowledge about cancer cachexia and to 
investigate the relationship between body composition and inflammation in two different 
samples; healthy individuals and patients with pancreatic cancer. By the use of observational 
studies, the conclusions are:  
I  An increase in fat percentage is associated with an elevation of adipokines (i.e. leptin) 
and inflammation (i.e. CRP) in overweight persons, but also among persons within the normal 
range of BMI. Hip circumference stood out as a surrogate measure for fat mass (%) in 
subjects within different BMI categories, and may be useful for identification of fat 
percentage in both overweigh and lean individuals. The results may indicate that adherence to 
a healthy lifestyle to prevent a high percentage of body fat is important for both lean and 
overweight people in order to reduce the risk for overweight-related chronic diseases  
II Patients with advanced pancreatic cancer experience an ongoing inflammation, and at 
the same time, they lose fat mass and FFM. However, patients classified as cachectic 
immediately after diagnosis did not have higher levels of inflammatory markers than patients 
classified as non-cachectic. Inflammation in the cancer patients may be caused by the 
presence of the tumor and may cause symptoms similar to cachexia. Moreover, increased 
inflammation may stimulate fat and muscle mass depletion. For this reason, an optimization 
of cancer treatment is essential in pancreatic cancer patients. 
III The two classifications showed good overall agreement in defining cachectic patients 
in this cohort with pancreatic cancer, and cachexia was associated with poorer survival 
according to both. Our findings suggest that the classification including CRP as a criterion 
was a better predictor of survival. Patients with no weight loss, reduced energy-intake or no 
sarcopenia and CRP<8 mg/L have the longest survival. Thus, clinical interventions should be 
directed to optimize these known risk factors. 
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